Ligand Pharmaceuticals LGND Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's deferred revenue?
- Ligand Pharmaceuticals (LGND) reported deferred revenue of $621K in Q1 2026.
- How has Ligand Pharmaceuticals's deferred revenue changed year-over-year?
- Ligand Pharmaceuticals's deferred revenue increased by 514.9% year-over-year, from $101K to $621K.
- What is the long-term trend for Ligand Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's deferred revenue has grown at a -53.8% compound annual growth rate (CAGR), from $29.44M to $621K.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.